Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy

Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy

Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease...

Full description

Bibliographic Details
Main Authors: Cinzia Milito, Francesco Cinetto, Andrea Palladino, Giulia Garzi, Alessandra Punziano, Gianluca Lagnese, Riccardo Scarpa, Marcello Rattazzi, Anna Maria Pesce, Federica Pulvirenti, Giulia Di Napoli, Giuseppe Spadaro, Rita Carsetti, Isabella Quinti
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Biomedicines
Subjects:
COVID-19
SARS-CoV-2
inborn errors of immunity
antibody deficiency
incidence
mortality rate
Online Access:https://www.mdpi.com/2227-9059/10/5/1026

Internet

https://www.mdpi.com/2227-9059/10/5/1026

Similar Items